Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,667 shares of common stock to cover withholding tax liabilities.

Summary

• On September 4, 2024, Richard A. Paulson, the President and CEO of Karyopharm Therapeutics Inc. (KPTI), sold 3,667 shares of common stock.
• The sale was executed at a price of $0.7218 per share.
• The transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021.
• The purpose of the sale was to cover withholding tax liabilities incurred upon the vesting of restricted stock units.
• Following the transaction, Paulson directly owns 1,139,214 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations and does not necessarily reflect a change in the executive's confidence in the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the stated reason for the sale.

Key Dates